Viatris Inc. recently concluded agreements for a comprehensive global research and development collaboration with Idorsia Ltd (SIX: IDIA), a transaction that was finalized on March 15, 2024. For detailed information regarding this significant transaction, please consult Viatris’ Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which has been submitted to the United States Securities and Exchange Commission.
R&D Event Mark your calendars for Viatris’ upcoming R&D Event scheduled for March 27, 2024, from 10 a.m. to noon ET, to be held in New York City.
During this event, key executives from Viatris will provide insights into the collaboration with Idorsia and other crucial aspects of the Company’s pipeline. Additionally, two distinguished thought leaders will deliver presentations. Attendees will have the opportunity to pose questions to the presenters at the conclusion of their talks.
The expert thought leaders scheduled to present at the event are:
Dr. Deepak L. Bhatt, MD, MPH, MBA, FACC, FAHA, FESC, MSCAI, renowned for his groundbreaking contributions to cardiovascular medicine and interventional cardiology. Dr. Bhatt currently serves as the Director of Mount Sinai Fuster Heart Hospital, where his work spans breakthroughs in interventional cardiology, heart disease prevention, vascular medicine, and heart failure. Dr. Anca Askanase, MD, a prominent figure in rheumatology and clinical research, serving as the founder and clinical director of Columbia University’s new Lupus Center and the Director of Rheumatology Clinical Trials. Dr. Askanase brings over 15 years of expertise in complex SLE, having trained and worked at New York University, where she directed clinical trials and treated challenging cases of SLE. Interested individuals can access a live webcast of the event at investor.viatris.com. Following the live event, an archived version will be available for a limited time at the same location.
About Viatris Viatris Inc. (NASDAQ: VTRS) is a leading global healthcare company dedicated to bridging the gap between generics and brands to address healthcare needs comprehensively. With a mission to promote healthier living worldwide, Viatris supplies high-quality medicines to approximately 1 billion patients annually, spanning all stages of life and addressing both acute and chronic conditions. With a diverse portfolio of medicines and a robust global supply chain, Viatris is committed to tackling enduring health challenges. Headquartered in the U.S., Viatris operates global centers in Pittsburgh, Shanghai, and Hyderabad, India.
